Cephalon: FTC's Challenge To Patent Settlements

Law360, New York (February 19, 2008, 12:00 AM EST) -- Last week, the Federal Trade Commission (“FTC” or “commission”) brought the latest in a series of challenges to patent settlements between brand and generic firms in the pharmaceutical industry.

The current suit challenges brand firm Cephalon’s settlements with four generic firms regarding the company’s $800 million drug Provigil. The FTC alleges that these settlements – and, in particular, the payments from Cephalon to the generic firms accompanying each of these settlements – caused the generic firms to delay their entry into the market until 2012....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.